scholarly journals Treatment Planning and Volumetric Response Assessment for Yttrium-90 Radioembolization: Semiautomated Determination of Liver Volume and Volume of Tumor Necrosis in Patients with Hepatic Malignancy

2010 ◽  
Vol 34 (2) ◽  
pp. 306-318 ◽  
Author(s):  
Wayne L. Monsky ◽  
Armando S. Garza ◽  
Isaac Kim ◽  
Shaun Loh ◽  
Tzu-Chun Lin ◽  
...  
Keyword(s):  
Treatment Planning ◽  
Tumor Necrosis ◽  
Liver Volume ◽  
Response Assessment ◽  
Hepatic Malignancy ◽  
Volumetric Response ◽  
Yttrium 90

Treatment of Metastases to the Vertebrae with Radiofrequency Ablation: Determination of Effectiveness by Evaluation of Tumor Necrosis – A Preliminary Result

2009 ◽  
Vol 2 (3) ◽  
pp. 191-194
Author(s):  
A. Gasbarrini ◽  
M. Cappuccio ◽  
H. Li ◽  
R. Donthineni ◽  
L. Boriani ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Tumor Necrosis

SU-E-T-316: Integration of Bioluminescence Imaging with Small Animal Radiotherapy for Treatment Planning and Response Assessment

2011 ◽  
Vol 38 (6Part15) ◽  
pp. 3560-3560
Author(s):  
J Noll ◽  
G Nelson ◽  
M Vilalta Colomer ◽  
R Ali ◽  
M Bazalova ◽  
...  
Keyword(s):  
Treatment Planning ◽  
Bioluminescence Imaging ◽  
Small Animal ◽  
Response Assessment ◽  
Small Animal Radiotherapy

Evaluation of number of target lesions to analyze in time to progression by RECIST

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6549-6549
Author(s):  
M. Gonen ◽  
L. Schwartz ◽  
R. Ford
Keyword(s):  
Response Assessment ◽  
Optimal Number ◽  
Response To Therapy ◽  
Phase Iii ◽  
Time To Progression ◽  
Overall Response ◽  
Considerable Controversy ◽  
Set Up

6549 Background: RECIST criteria were designed to evaluated tumor shrinkage and response to therapy by measurement of multiple target lesions, evaluation of non target and new lesions. There is considerable controversy surrounding the optimal number of lesions to assess response, with RECIST requiring the measurement of up to 10 target lesions. These guidelines were set up to evaluate the endpoint of best overall response. Increasingly, time to progression has become an important endpoint in oncology trials. We evaluated the optimal number of lesions to measure to accurately and reproducibly assess time to progression. Methods: We evaluated target lesions metastases in 105 patients enrolled on a Phase III clinical trial. All patients underwent CT at baseline and standard follow up scans until progression. Target lesions were measured unidimensionally and response was assessed according to RECIST by 2 independent Radiologists. A total of 519 target lesions were assessed. Response was calculated according to the rules of target lesions (up to 10) by RECIST, utilizing the 2 largest lesions and randomly selecting 2 target lesions. Results: Using the 2 largest lesions, time to progression was concordant in 83% of cases. The 2 Radiologists determined the two same largest lesions in 89% of cases. Since the determination of the largest or the same target lesions is not always possible or performed, a random selection of 2 target lesions demonstrated a 76% concordance in the time to progression. Conclusions: Measurement of time to progression may have a greater degree of variability than measurement of best overall response and therefore measurement of minimal selected lesions will lead to a great variability in response assessment. No significant financial relationships to disclose.

Roentgenologic Determination of the Liver Volume

1961 ◽  
Vol Original Series, Volume 55 (1) ◽  
pp. 49-56
Author(s):  
L. Walk
Keyword(s):  
Liver Volume
Sign in / Sign up

Export Citation Format

Share Document